Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of MT-5111 in HER2-positive Solid Tumors (MT-5111)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04029922
Recruitment Status : Recruiting
First Posted : July 23, 2019
Last Update Posted : November 20, 2019
Sponsor:
Information provided by (Responsible Party):
Molecular Templates, Inc.

Brief Summary:
This will be a Phase 1, first in human, open-label, dose escalation and expansion study of MT-5111 (a recombinant fusion protein) in subjects with HER2-positive solid tumors.

Condition or disease Intervention/treatment Phase
HER2-positive Solid Cancers Drug: MT-5111 (experimental study drug) Phase 1

Detailed Description:

This study will be conducted in two sequential parts:

  • Part 1 (Dose Escalation): The purpose of Part 1 is to determine the Phase 2 dose (RP2D) to be used in Part 2. Part 1 will include any type of HER2-positive solid cancer.
  • Part 2 (Dose Expansion): The purpose of Part 2 is to confirm the safety and tolerability of the RP2D of MT-5111. Part 2 will include any type of HER2-positive solid cancer, including breast cancer, gastric or gastroesophageal adenocarcinomas (GEA).

Up to 140 eligible subjects will be identified and treated through competitive enrollment at multiple study centers.

In Parts 1 and 2 of the study, a subject may participate for the following four periods:

  • Screening (up to 28 days before first dose of MT-5111)
  • Treatment period (active period where a subject will receive doses of MT-5111 over a 21-day treatment cycle)
  • Follow-up (30 days after last dose of MT-5111)
  • Long-term follow-up (up to 24 months after the last dose of MT-5111)

MT-5111 will be given as an intravenous (IV) infusion over about 30 minutes on the same day every week (i.e., on day 1, day 8 and day 15 of each cycle, a cycle being defined as 21 days). A subject can continue receiving MT-5111 as long as it is well-tolerated, their disease has not worsened, or until the subject decides they no longer want to participate in the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 140 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: MT-5111 (active drug)
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Open-label, Multicenter Dose Escalation Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid Tumors
Actual Study Start Date : November 12, 2019
Estimated Primary Completion Date : May 2023
Estimated Study Completion Date : May 2025

Arm Intervention/treatment
Experimental: Arm 1- Dose Escalation

The dose escalation part of the study is aimed at determining the Recommended Phase 2 Dose (RP2D) of MT-5111.

The assigned dose level of MT-5111 will be given as an intravenous (IV) infusion over about 30 minutes on the same day every week (i.e., on day 1, day 8 and day 15 of each cycle).

Drug: MT-5111 (experimental study drug)
Experimental treatment with MT-5111

Experimental: Arm 1- Dose Expansion

The dose expansion part of the study will begin after completion of the dose escalation phase to confirm the safety and tolerability of the RP2D.

The RP2D dose level of MT-5111 will be given as an intravenous (IV) infusion over about 30 minutes on the same day every week (i.e., on day 1, day 8 and day 15 of each cycle).

Drug: MT-5111 (experimental study drug)
Experimental treatment with MT-5111




Primary Outcome Measures :
  1. To evaluate safety and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) [ Time Frame: 21 day cycle ]
    Evaluation of safety of MT-5111 as measured by number of subjects with adverse events using Common Terminology Criteria for Adverse Events (CTCAE) v 5.0

  2. To evaluate tolerability and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) [ Time Frame: 21 day cycle ]
    Evaluation of tolerability of MT-5111 as measured by number of subjects with dose limiting toxicities (DLTs)


Secondary Outcome Measures :
  1. PK as measured by concentrations of free MT-5111 (Maximum Plasma Concentration [Cmax]) [ Time Frame: Day 1, Day 8 (cycle 1 only), and Day 15 (cycle 1 only) in Each 21-Day cycle ]
    Evaluation of the pharmacokinetic profile of MT-5111

  2. PK as measured by concentrations of free MT-5111 (Time to reach maximum concentration after drug administration [Tmax]) [ Time Frame: Day 1, Day 8 (cycle 1 only), and Day 15 (cycle 1 only) in Each 21-Day cycle ]
    Evaluation of the pharmacokinetic profile of MT-5111

  3. PK as measured by concentrations of free MT-5111 (Area Under the Curve [AUC]) [ Time Frame: Day 1, Day 8 (cycle 1 only), and Day 15 (cycle 1 only) in Each 21-Day cycle ]
    Evaluation of the pharmacokinetic profile of MT-5111

  4. To evaluate the tumor response to MT-5111 [ Time Frame: Screening, approximately every 6 weeks, at End of Treatment and 30 days after the last dose ]
    Objective response rate (ORR) defined as the proportion of subjects with either a complete response or a partial response as determined by investigator assessment

  5. To evaluate the immunogenicity of MT-5111 [ Time Frame: Screening (baseline), Day 1 of each 21 day cycle, at the End of Treatment and the Follow-up Visit ]
    Immunogenicity as measured by MT-5111 (anti-drug antibody [ADA] titer)

  6. To evaluate the immunogenicity of MT-5111 [ Time Frame: Screening (baseline), Day 1 of each 21 day cycle, at the End of Treatment and the Follow-up Visit ]
    Immunogenicity as measured by MT-5111 (neutralizing antibody [NAb])


Other Outcome Measures:
  1. To correlate the pharmacodynamic markers of cancer under study (for breast cancer subjects using historic data, if available) [ Time Frame: Screening (baseline) ]
    The expression of HER2, Estrogen Receptor (ER), Progesterone Receptor (PgR) and Ki67 (exploratory) on the tumor cell analyzed by immunohistochemistry

  2. To correlate the pharmacodynamic markers of cancer under study relationship for MT-5111 using the PK, pharmacodynamics, safety, and tumor response variables. [ Time Frame: Screening (baseline), every 6 weeks (± 1 week) and within 7 days of the EoT Visit. ]
    Serum-HER2 (s-HER2)

  3. If warranted by the study results, to evaluate the exposure-response relationship for MT-5111 [ Time Frame: Screening (baseline), every 6 weeks (± 1 week) and within 7 days of the EoT Visit. ]
    Analyze data collected for all primary, secondary and exploratory endpoints using the PK, pharmacodynamics, safety, and tumor response variables



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed, unresectable, locally advanced or metastatic solid cancers:

    • Part 1 (Dose-Escalation): All HER2-positive solid cancers are eligible
    • Part 2 (Dose-Expansion): Any type of HER2-positive solid cancer, including breast cancer, gastric or gastroesophageal adenocarcinomas (GEA).
  2. HER2-positive in the latest tumor sample tested for HER2 (testing to be done on a metastatic lesion in cases of metastatic cancers).
  3. Relapsed or refractory to or intolerant of existing therapy(ies)
  4. At least 1 measurable or evaluable lesion according to RECIST 1.1
  5. ECOG performance score of ≤ 1
  6. Bone marrow function:

    • Absolute neutrophil count (ANC) ≥ 1,000/mm3
    • Platelet count ≥ 75,000 mm³ and
    • Hemoglobin ≥ 8.0 g/dL
    • No red blood cell transfusion within 4 weeks of study treatment start is allowed
  7. Kidney function:

    • (eGFR) ≥ 50 mL/min calculated by the Cockcroft-Gault formula
    • Subjects with CLcr ≥ 50 mL/min will be eligible irrespective of the eGFR result
  8. Cardiac Function:

    • Left ventricular ejection fraction (LVEF) ≥ 55% on the multigated acquisition (MUGA) scan (preferred) or echocardiogram (ECHO) assessment, and
    • QTcF ≤ 480 ms for women and QTcF ≤ 450 ms for men [average from three QTcF values on the triplicate 12-lead electrocardiogram (ECG)] at baseline
  9. Hepatic function:

    1. Total bilirubin ≤ 1.5 x ULN, and
    2. AST ≤ 3 x ULN and ALT ≤ 3 x ULN

      • < 5 x ULN (if hepatic metastases)

Exclusion Criteria:

  1. History or current evidence of another tumor that is histologically distinct from the tumor under study
  2. Current evidence of new or growing CNS metastases during screening

    -Subjects with known CNS metastases will be eligible if they meet specified criteria

  3. Evidence of CTCAE Grade >1 toxicity before the start of treatment, except for hair loss and those Grade 2 toxicities listed as permitted in other eligibility criteria
  4. History or evidence of significant cardiovascular disease
  5. Current evidence of active, uncontrolled hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV) (evidenced by detectable viral load by PCR) or acquired immunodeficiency syndrome (AIDS) related illness
  6. Current evidence of ≥ grade 2 underlying pulmonary disease
  7. Certain exclusionary prior treatments

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04029922


Contacts
Layout table for location contacts
Contact: Joshua Pelham (862) 283-0448 joshua.pelham@mtem.com
Contact: Kristen Quigley (862) 203-7537 kristen.quigley@mtem.com

Locations
Layout table for location information
United States, California
Cedars-Sinai Medical Center Recruiting
Santa Monica, California, United States, 90048
Contact: Hilary Lachoff    310-967-0621    Hilary.lachoff@cshs.org   
UCLA Hematology & Oncology Recruiting
Santa Monica, California, United States, 90404
Contact: Lisa Yonemoto    310-794-6500    lyonemoto@mednet.ucla.edu   
United States, Florida
Sylvester Comprehensive Cancer Center (University of Miami) Recruiting
Coral Gables, Florida, United States, 33146
Contact: Frances Valdes    305-243-5302    fvalbini@med.miami.edu   
United States, Missouri
Washington University Recruiting
Saint Louis, Missouri, United States, 63130
Contact: Katlyn Kraft Kraft, CCRP    314-747-5440    katlyn.kraft@wustl.edu   
United States, Tennessee
Sarah Cannon Research Institute Recruiting
Nashville, Tennessee, United States, 37203
Contact: Dee McComb    844-482-4812    CANN.ResearchReferrals@scresearch.net   
United States, Texas
Mary Crowley Cancer Research Recruiting
Dallas, Texas, United States, 75251
Contact: Referral Office    972-566-3000    referral@marycrowley.org   
The University of Texas Health Science Center Recruiting
San Antonio, Texas, United States, 78229
Contact: Maggie Tomasini    210-450-5962    tomasinim@uthscsa.edu   
Contact: Jennifer Moseley    210-450-1799    moseleyj@uthscsa.edu   
Sponsors and Collaborators
Molecular Templates, Inc.
Layout table for additonal information
Responsible Party: Molecular Templates, Inc.
ClinicalTrials.gov Identifier: NCT04029922    
Other Study ID Numbers: MT-5111_001
First Posted: July 23, 2019    Key Record Dates
Last Update Posted: November 20, 2019
Last Verified: November 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No